Sickle cell hemoglobin (HbS) is the result of a single nucleotide change (GAG GTG) in the beta-globin gene, where valine replaces glutamic acid at the sixth amino acid position in the beta-globin chain. Sickle cell disease is a growing global health problem. The World Health Organization has estimated that 7% of the world population has the mutation and 300,000400,000 affected children are born every year. The disease progresses towards a severe chronic hemolytic anemia, and it shows a heterogeneous clinical course, related with different genetic factors. Despite the fact that all subjects with sickle cell disease (SCD) have the same single base pair mutation in the DNA, we further confirmed here that the severity of the clinical and hematological manifestations is extremely variable. Increasing evidence has indicated a role of oxidative stress in the vascular pathophysiology of SCD. The vascular endothelium is central to disease pathogenesis because it displays adhesion molecules for blood cells, balances procoagulant and anticoagulant properties of the vessel wall and regulates vascular homeostasis by synthesizing vasoconstricting and vasodilating substances.In addition, recent studies support the existence of a hyperoxidative status in SCD patients that may account, at least in part, for the clinical manifestations of these patients. Moreover, SCD patients with mild clinical outcomes were associated with low oxidative status, whereas high oxidative stress was related to severe phenotypes. Thus, the use of oxidative stress biomarkers may be important in the evaluation of the clinical condition of SCD patients, whereas the use of therapies to improve their redox status and increase NO bioavailability would be beneficial to reduce the severity of sickle disease. The global burden of SCD is now significantly increased and, thus, it is currently a public health problem around the world. This disease has passed from being a problem of the developing countries to affect many people in developed countries. This book summarizes the current epidemiology status and the latest discoveries in the pathophysiology of SCD, and the potential therapies that may improve the clinical course of this disease.

Defined as red blood cell break down and the release of hemoglobin and intracellular contents into the plasma, haemolysis can seriously impact patient care as well as the laboratory's reputation through its affect on test results. Therefore, the European Preanalytical Scientific Committee, in collaboration with the International Federation of Clinical Chemistry Working Group on Patient Safety, have designed a questionnaire to collect data on prevalence and management of haemolytic specimens referred to the clinical laboratories for clinical chemistry testing. The new book will help identify the areas where haemolysis occurs most frequently, which can, in turn, guide further analysis about why it is occurring. Once these elements are known, practices and procedures can be implemented to dramatically reduce haemolysis and avoid erroneous laboratory results affecting patient care and increasing laboratory costs.

In the human body, iron is present in all cells and has several vital functions: as a carrier of oxygen to the tissues from the lungs in the form of hemoglobin; as a transport medium for electrons within the cells in the form of cytochromes and as an integral part of enzyme reactions in various tissues. Too little iron can interfere with these vital functions and lead to morbidity and death. This book presents current research from across the globe in the study of iron deficiency, including iron deficiency anemia in pregnant women and in gastric bypass surgery patients; the metabolic adjustment under Fe deficiency in roots of dicotyledonous plants and strategies for the fortification of food with iron.

Hemostasis (coagulation and fibrinolysis) is of importance in a broad range of medical disciplines. A high-quality hemostasis diagnosis enables a good therapy, which can be rather complicated without laboratory help. This yearbook gathers important contributions in this field and presents them in a coherent and logical format.

For many years the mammalian blood cell system has provided cell biologists and haematologists with one of the best experimental models in which to unravel how one stem cell -- the hematopoietic stem cell -- gives rise to many different types of progeny. Numerous models of lineage relationships have emerged, but the most influential of these, in which differentiating cells undergo a series of binary choices, has been increasingly challenged in recent years -- to the extent that the accumulation of new findings recently culminated in a Nature commentary suggesting that "the latest research will necessitate revision of textbook accounts". This book brings together contributions from many leading experts in the field of blood cell development who each discuss both the overall process of hematopoiesis and the origins and development of each of the cells of the blood and immune systems. It describes how new molecular, cellular and -- particularly -- transgenic tools are helping us understand the processes that control the lineage fates of hematopoietic stem and progenitor cells and how lineage-committed progeny develop along particular maturation pathways.

Granulocytes are a category of white blood cells characterised by the presence of granules in their cytoplasm. This book examines the characteristics of eosinophil granulocytes, its biological functions, its role in inflammation and its clinical significance in children. This book also reviews the role of granulocytes on the onset of tissue-destructive diseases when exposed to stress. In addition to the cases of disease, some physiological phenomena are also responsible for the stress-induced granulocytosis. Thus this book will also expands upon the role of granulocytes associated with various diseases and some physiological responses. Other topics discussed in this book include the role of basophil, the minute group of granulocyte, in tropical infections and in immune regulations; polymorphonuclear neutrophilic granulocytes (neutrophils), which are the most dangerous cells in the organism and their role in transient states of autoimmunity, and the effects of nucleoli change during differentiation and maturation of granulocytes.

This book is a completely revised new edition of the definitive reference on disorders of hemoglobin. Authored by world-renowned experts, the book focuses on basic science aspects and clinical features of hemoglobinopathies, covering diagnosis, treatment, and future applications of current research. While the second edition continues to address the important molecular, cellular, and genetic components, coverage of clinical issues has been significantly expanded, and there is more practical emphasis on diagnosis and management throughout. The book opens with a review of the scientific underpinnings. Pathophysiology of common hemoglobin disorders is discussed next in an entirely new section devoted to vascular biology, the erythrocyte membrane, nitric oxide biology, and hemolysis. Four sections deal with and thalassemia, sickle cell disease, and related conditions, followed by special topics. The second edition concludes with current and developing approaches to treatment, incorporating new agents for iron chelation, methods to induce fetal hemoglobin production, novel treatment approaches, stem cell transplantation, and progress in gene therapy.

Hematopoietic stem cell transplantation (HSCT) is the transplantation of blood stem cells derived from the bone marrow (that is, bone marrow transplantation) or blood. Stem cell transplantation is a medical procedure in the fields of haematology and oncology, most often performed for people with diseases of the blood, bone marrow, or certain types of cancer. Stem cell transplantation was pioneered using bone-marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research Center from the 1950s through the 1970s led by E. Donnall Thomas, whose work was later recognised with a Nobel Prize in Physiology and Medicine. Thomas' work showed that bone marrow cells infused intravenously could repopulate the bone marrow and produce new blood cells. His work also reduced the likelihood of developing a life-threatening complication called Graft-versus-host disease. With the availability of the stem cell growth factors GM-CSF and G-CSF, most hematopoeitic stem cell transplantation procedures are now performed using stem cells collected from the peripheral blood, rather than from the bone marrow. Collecting stem cells provides a bigger graft, and does not require that the donor be subjected to general anaesthesia to collect the graft. Hematopoeitic stem cell transplantation remains a risky procedure with many possible complications; it has always been reserved for patients with life-threatening diseases. This book presents recent leading research in the field.

Warfarin (also known under the brand names of Coumadin, Jantoven, Marevan, and Waran) is an anticoagulant medication that is administered orally or, very rarely, by injection. It is used for the prophylaxis of thrombosis and embolism in many disorders. Its activity has to be monitored by frequent blood testing for the international normalised ratio (INR). It is named for the Wisconsin Alumni Research Foundation. Warfarin is a synthetic derivative of coumarin, a chemical found naturally in many plants, notably woodruff (Galium odoratum, Rubiaceae), and at lower levels in liquorice, lavender and various other species. Warfarin was originally developed as a rat poison; however, more modern poisons are much more potent and toxic (e.g., brodifacoum). Warfarin and contemporary rodenticides belong to the same class of drugs (coumarins) and both decrease blood coagulation by interfering with vitamin K metabolism. For this reason, drugs in this class are also referred to as vitamin K antagonists.

There are two dominant aspects which conclude the coagulation cascade: the importance of the tissue factor pathway in initiating clotting and the interaction between pathways. Two main pathways are recognised the extrinsic and the intrinsic. At the side of vascular injury endothelial cells are converted in a pro-thrombotic state or become detached to exposed circulating blood to thrombogenic constituents of the sub-endothelial matrix. Activation of platelets and formation of fibrin occur simultaneously and interdependently to effect haemostasis. The activated platelets express the receptor GPIb-IX-V complex that further strengthens the adhesion by linking to von Willebrand factor expressed on the sub-endothelial matrix. A platelet monolayer which covers the injured area recruits and aggregates activated platelets to form a platelet plug by linking to fibrinogen molecules. Activation of a series of inactive precursors leads to the formation of thrombin that cleaves fibrinogen to fibrin. The sequence of reactions interacting between factor X represents the common pathway of coagulation. Factor X can be activated in turn by either the tissue factor pathway or the contact activation pathway of coagulation, which is initiated by the complex of tissue factor and factor VIIa. The latter involves a series of zymogen protease reactions that are initiated by contact activation of factor XII to XIIa. As the haemostatic process starts, a series of inhibitory mechanisms is activated involving antithrombin III, protein C, protein S, the tissue factor pathway inhibitors 1 and 2 and platelet inhibitors (prostaglandin I2, nitric oxide). Fibrinolytic mechanisms assure the clot's remodelling and elimination in the prospect of restoring the vessels patency. During the fibrinolytic process plasmin cleaves polymerised fibrin to fibrin degradation products. The liver plays a predominant role in the regulation of haemostasis. By producing most clotting factors (except tissue factor TF) and inhibitors (antithrombin III, protein C, protein S, C1 inhibitor), as well as a number of the proteins involved in fibrinolysis (plasminogen, a2-antiplasmin), and by clearing from the bloodstream activated enzymes involved in clotting or fibrinolysis, the liver protects against both bleeding and overwhelming activation of coagulation. There is a common bleeding profile emerging in the overwhelming majority of liver diseases. The severity of documented coagulation disorders varies analogically to the degree of the hepatocellular injury. The importance of the coagulopathy is underlined by the incorporation of the coagulation parameters into prognostic scores assessing fulminant hepatic failure and cirrhosis. The purpose of this book is to review the coagulation profile in acute liver failure, liver cirrhosis, autoimmune cholestatic, viral and various hepatic diseases. Diagnostic and therapeutic modalities in coagulation defects in liver diseases are also reviewed.

This new book brings together leading research from around the globe. Leukaemia is a cancer that begins in blood cells. In people with leukaemia, the bone marrow produces abnormal white blood cells. The abnormal cells are leukaemia cells. At first, leukaemia cells function almost normally. In time, they may crowd out normal white blood cells, red blood cells, and platelets. The scope of the book includes the four common types of leukaemia: Chronic lymphocytic leukaemia (chronic lymphoblastic leukaemia, CLL) most often affecting people over age 55. Chronic myeloid leukaemia (chronic myelogenous leukaemia, CML) affects mainly adults. Acute lymphocytic leukaemia (acute lymphoblastic leukaemia, ALL) the most common type of leukaemia in young children. Acute myeloid leukaemia (acute myelogenous leukaemia, AML) which occurs in both adults and children. New advances in diagnosis, pathogenesis and therapy are presented.

Angiogenesis -- the growth of new blood vessels -- is an important natural process occurring in the body, both for health and as related to disease. Angiogenesis occurs in the healthy body to help heal wounds and to help restore blood flow to tissues after injury or insult. In females, Angiogenesis also occurs during the monthly reproductive cycle (to rebuild the uterus lining, to mature the egg during ovulation) and during pregnancy (to build the placenta, the circulation between mother and foetus). The healthy body controls Angiogenesis through a series of 'on' and 'off' switches. The main 'on' switches are known as Angiogenesis-stimulating growth factors. The main 'off' switches are known as Angiogenesis inhibitors. When angiogenic growth factors are produced in excess of angiogenesis inhibitors the balance is tipped in favour of blood vessel growth. When inhibitors are present in excess of stimulators, angiogenesis is stopped. The normal, healthy body maintains a perfect balance of angiogenesis modulators. In general, angiogenesis is 'turned off' by the production of more inhibitors than stimulators. Tumour angiogenesis is the proliferation of a network of blood vessels that penetrates into cancerous growths, supplying nutrients and oxygen and removing waste products. Tumour angiogenesis actually starts with cancerous tumour cells releasing molecules that send signals to surrounding normal host tissue. This signalling activates certain genes in the host tissue that, in turn, cause proteins to encourage growth of new blood vessels. This new book examines its angiogenesis within the context of theory and its applications to cancer treatment.

Each year thousands are told they suffer from anemia, but most have only a vague understanding of the condition. In fact, "anemia" is a generic term that includes myriad specific diseases, each of which has its own story regarding cause, manifestations, and treatments.Understanding Anemia gently builds upon elementary knowledge of biology to provide the general reader with a fairly sophisticated understanding of the various causes of anemia, of the methods used to make diagnoses, and of the principles of treatment. The book begins with a definition of anemia and a brief history of the scientific study of blood. It explains how the doctor makes the diagnosis and details the main types of anemia. Since the different conditions result from the failure of various organs, the reader will come away with a surprisingly broad understanding of human anatomy and physiology, encompassing the digestive, circulatory, and immune systems, nutrition, biochemistry, and heredity.Features: Specific anemias: iron deficiency, vitamin deficiencies, hemolytic anemias, hereditary anemias, and others Helpful appendices: a practical guide to the metric system, a brief review of general cell biology, a table of normal values in commonly ordered lab tests, a description of the bone marrow biopsy procedure, a list of pitfalls a doctor faces during the evaluation of the anemic patient, resources for further study (both in print and on the Internet)

Ed Uthman is director of the medical laboratory at Polly Ryon Memorial Hospital in Richmond, Texas. He is an adjunct assistant professor of pathology at the University of Texas School of Medicine, Houston.

This book provides an updated overview of eicosanoid metabolism. It also presents a timely discussion of eicosanoid metabolism in the process of tumor cell metastasis, in chemoprotection and radioprotection associated with cancer therapy, and in cell differentiation. The book focuses on the role of eicosanoids in the immunology of malignant disease. This includes how various immune cell populations in cancer are affected by the secretion and action of various eicosanoids and metabolites of eicosanoids and how these processes may be affected by various pharmacological manipulations and interventions to augment anti-tumor immunity. Head and neck cancer is covered in great detail to illustrate a cancer in humans where these considerations are particularly relevant. This important volume demonstrates that the principal factor in cancer patient immunologic deficiency is related to excess secretion by monocytes of prostaglandins.

Systematisch aufgebaut und klar strukturiert stellt das Standardwerk das Gebiet der Transfusionsmedizin und Immunhamatologie in seiner Gesamtheit dar: von den Grundlagen der Transfusionsmedizin, der Therapie mit Blut, Blutkomponenten und Blutbestandteilen uber Blut sparende Massnahmen bis hin zu unerwunschten Wirkungen von Blutubertragungen. Das einzige deutschsprachige Werk zu diesem Fachgebiet wurde fur die 4. Auflage komplett aktualisiert und erweitert. Der Anhang enthalt Nachweise fur alle relevanten Antigene und Antikorper.
"

A cross between a dictionary and an encyclopedia, Desk Reference for Hematology, Second Edition presents a concise yet thorough examination of hematology and its relationship with other systems and disorders. The 1500 alphabetically listed articles provide quick and easy access to expert information, the 150 tables put precise data at your fingertips, and the 100 figures are a visual tool that clarify the text. The book also includes 500 references on state-of-the-art guidelines and recent developments. See what's new in the Second Edition: * Revised articles emphasizing genetics, physiology, pathological mechanisms * Updated coverage of treatments for leukemia, lymphoma, coagulation, and thrombotic disorders * Hundreds of completely new articles, new illustrations, and new explanatory diagrams as well as revised tables Completely revised, this edition covers hematopoiesis, red blood cells, granulocytes, lymphocytes, platelets and hemostasis where the respective physiology is described anemias, leukemias, lymphomas, auto-immune disorders, hemorrhagic disorders, and thrombosis where etiology, pathogenesis, diagnosis and treatment is described. The book includes coverage of blood groups and the practice of blood component therapy. The editor pays particular attention to recent developments in hematological molecular genetics and leukemogenesis. The information is cross-referenced with words highlighted in bold face within an article to indicate that further information on the subject is available under the emboldened heading. A separate table provides common abbreviations used widely throughout the text. Carefully designed for ease of use, the book provides speedy access to authoritative information on the scientific basis of blood disorders and their treatment.

Depuis sa premiere edition en 1983, il y a plus de vingt ans, le Manuel de securite biologique en laboratoire a donne des conseils pratiques sur les techniques de securite a appliquer dans les laboratoires a tous les niveaux. La bonne application des techniques microbiologiques et l'utilisation de l'equipement de securite biologique par du personnel bien entraine restent les piliers de la securite en laboratoire. Toutefois, la mondialisation, les progres technologiques, l'apparition de nouvelles maladies et les graves menaces liees a une utilisation ou a une mise en circulation deliberees de micro-organismes ou de toxines ont impose de revoir les procedures. Pour cette nouvelle edition, le manuel a donc ete considerablement revu et developpe.Le manuel couvre desormais aussi l'evaluation du risque et l'utilisation sans risque des techniques faisant appel a l'ADN recombinant. Il donne par ailleurs des lignes directrices pour la mise en service et la certification des laboratoires. Il presente les concepts de la securite biologique et les reglementations internationales les plus recentes sur le transport des matieres infectieuses. On y a egalement integre les informations sur la securite dans les laboratoires d'analyses medicales, publiees auparavant dans d'autres documents de l'OMS. Nous esperons que le manuel continuera d'inciter les pays a instituer des programmes de securite biologique et des codes nationaux de bonnes pratiques pour manipuler sans danger les matieres potentiellement infectieuses."